mRNA Products

Description: eGFP mRNA (5' CAP) is a high-quality messenger RNA designed for efficient expression of the enhanced green fluorescent protein (eGFP) in mammalian cells. This mRNA is produced through in vitro transcription and features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which significantly enhance its stability and translation efficiency. The Cap 1 structure mimics the natural cap found in eukaryotic mRNA, reducing immune responses and improving protein expression. eGFP, a widely used fluorescent reporter gene derived from the jellyfish Aequorea victoria, has excitation and emission wavelengths of 488 nm and 509 nm, respectively. When transfected into cells, eGFP mRNA can rapidly express bright green fluorescence without the risk of genomic integration, making it a superior choice compared to DNA-based expression systems. This feature allows for real-time monitoring of gene expression and cellular processes in live cells and tissues. The mRNA is optimized for use in various applications, including gene regulation and functional studies, where it serves as a reporter gene to monitor gene expression and cellular processes. It is also used to evaluate the efficiency of different transfection reagents and to monitor gene expression in live cells and tissues for in vivo imaging studies.

CAT: BRP-02516

Appearance: Colorless and transparent liquid

Concentration: 1.0 mg/mL

Description: Fluc mRNA (5' CAP) is a specialized messenger RNA designed for efficient expression of firefly luciferase (Fluc), a widely used bioluminescent reporter gene. This mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which enhance its stability and translation efficiency. The Cap 1 structure mimics the natural cap found in eukaryotic mRNA, reducing immune responses and improving protein expression. Fluc mRNA can express proteins directly in the cytoplasm without relying on a promoter, resulting in faster protein expression compared to DNA transfection. The expressed luciferase protein catalyzes the oxidation of luciferin to produce bioluminescence with a wavelength of approximately 550-570 nm, allowing for highly sensitive detection of gene expression. This makes Fluc mRNA an ideal tool for studying gene regulation, promoter activity, and miRNA target validation. It is also commonly used in dual-luciferase reporter systems, where it can be paired with another luciferase (such as Renilla luciferase) to provide an internal control, thereby reducing experimental variability. This product is commonly used as a reporter gene in various research applications, including gene expression studies and cell viability assays.

CAT: BRP-02517

Appearance: Colorless and transparent liquid

Concentration: 1.0 mg/mL

Description: eGFP mRNA with N1-Me-pUTP (5' CAP) is a highly optimized messenger RNA designed for efficient expression of the enhanced green fluorescent protein (eGFP) in mammalian cells. This mRNA is produced through in vitro transcription and features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which enhance its stability and translation efficiency. The incorporation of N1-Methyl-pseudouridine (N1-Me-pUTP) replaces natural uridine, effectively reducing the immune response in mammalian cells while further stabilizing the mRNA. eGFP is a widely used reporter gene with excitation and emission wavelengths of 488 nm and 509 nm, respectively. When transfected into cells, eGFP mRNA can rapidly express bright green fluorescence without the risk of genomic integration, making it an ideal tool for monitoring transfection efficiency and protein expression. This optimized mRNA is suitable for applications such as studying gene regulation, evaluating transfection and delivery efficiency, and conducting in vivo imaging studies.

CAT: BRP-02518

Appearance: Colorless and transparent liquid

Concentration: 1.0 mg/mL

Description: Fluc mRNA with N1-Me-pUTP (5' CAP) is a highly optimized messenger RNA designed for efficient expression of firefly luciferase (Fluc) in various biological applications. This mRNA is produced through in vitro transcription and features a Cap 1 structure at the 5' end, which enhances its stability and translation efficiency. Additionally, it contains a poly(A) tail at the 3' end, further stabilizing the mRNA and promoting efficient translation. A key feature of this mRNA is the incorporation of N1-Methyl-pseudouridine (N1-Me-pUTP), which replaces natural uridine triphosphate (UTP) during transcription. This modification significantly reduces the immune response in mammalian cells while enhancing mRNA stability and translation efficiency. The Cap 1 structure and N1-Me-pUTP together provide a more stable and efficient mRNA platform, making it suitable for applications such as gene expression studies, transfection efficiency assessments, and in vivo imaging.

CAT: BRP-02519

Concentration: 1.0 mg/mL

Description: Enhanced Green Fluorescent Protein (eGFP) IVT mRNA is a versatile tool for studying gene expression and cellular processes. It is synthesized through in vitro transcription (IVT) using a plasmid template that contains the eGFP gene flanked by a 5' UTR and a 3' UTR, typically derived from human β-globin RNA, along with a poly(A) tail to enhance stability and translation efficiency. The mRNA is often capped co-transcriptionally with anti-reverse cap analog (ARCA) to mimic the natural cap structure of eukaryotic mRNA, which enhances translation efficiency and reduces immune activation. Additionally, the mRNA can be chemically modified, such as by replacing uridine with pseudouridine (Ψ) and cytidine with 5-methyl-cytidine, to further reduce immunogenicity and improve stability. eGFP IVT mRNA is widely used as a reporter gene mRNA to monitor transfection efficiency and protein expression in various cell types. It allows for real-time visualization of gene expression using fluorescence microscopy due to the characteristic excitation/emission wavelengths of eGFP (488 nm/509 nm). This makes it an essential tool in molecular biology for applications such as studying gene regulation, evaluating transfection methods, and developing mRNA-based therapies.

CAT: BRP-02520

Appearance: Liquid

Concentration: 1 μg/μL

Description: EGFP IVT mRNA (m1Ψ substitution) is a highly optimized messenger RNA designed for efficient expression of the enhanced green fluorescent protein (eGFP). This mRNA is produced through in vitro transcription (IVT) and features several key modifications to enhance its stability, translation efficiency, and reduce immunogenicity. The incorporation of m1Ψ replaces uridine, which significantly reduces the activation of innate immune sensors such as 2'-5'-oligoadenylate synthetase (OAS) and RNA-dependent protein kinase (PKR), thereby minimizing immune responses. Additionally, m1Ψ has been shown to increase translation efficiency and mRNA half-life by stabilizing the secondary structure of the mRNA. The mRNA also features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, further enhancing its stability and promoting efficient translation. eGFP IVT mRNA with m1Ψ substitution is ideal for monitoring gene expression and cellular processes in real-time using fluorescence microscopy (excitation/emission wavelengths: 488 nm/509 nm). It is commonly used as a reporter gene to evaluate transfection efficiency and study gene regulation in various cell types. This optimized mRNA is suitable for both in vitro and in vivo studies, providing a versatile tool for molecular biology and translational medicine.

CAT: BRP-02521

Appearance: Liquid

Concentration: 1 μg/μL

Description: Zebrafish eGFP IVT mRNA is a highly optimized reporter gene mRNA designed for efficient expression of the enhanced green fluorescent protein (eGFP) in zebrafish embryos. This mRNA is produced through in vitro transcription (IVT) using a linearized pCS2+ vector containing the eGFP gene under the control of the SP6 promoter. The mRNA features a Cap 0 or Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. These modifications ensure that the mRNA remains stable and efficiently translated into the eGFP protein, which can be used for visualizing gene expression and cellular processes in real-time using fluorescence microscopy. As a reporter gene mRNA, eGFP IVT mRNA is widely used in zebrafish models for several applications. It can be injected into one-cell stage embryos to study gene function through ectopic expression or overexpression experiments. The eGFP protein, with excitation and emission wavelengths of 488 nm and 509 nm, respectively, allows for easy visualization of protein expression and localization in live embryos. This feature makes it an ideal tool for monitoring transfection efficiency, studying gene regulation, and evaluating the effects of different mRNA modifications on protein expression levels.

CAT: BRP-02522

Appearance: Liquid

Concentration: 1 μg/μL

Description: mCherry IVT mRNA is a versatile reporter gene mRNA designed for efficient expression of the mCherry protein, a monomeric red fluorescent protein derived from Discosoma. This mRNA is produced through in vitro transcription (IVT) and features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The mCherry protein has excitation and emission wavelengths of 587 nm and 610 nm, respectively, making it an ideal tool for fluorescence microscopy and live-cell imaging. As a reporter gene mRNA, mCherry IVT mRNA is widely used in studies involving gene transfection, protein expression analysis, and the evaluation of cellular responses to different transfection reagents. It allows researchers to monitor gene expression and cellular processes in real-time, providing valuable insights into cellular dynamics and gene regulation. It has been validated for high-level expression in various cell types, making it suitable for applications such as transfection efficiency studies and protein expression analysis.

CAT: BRP-02523

Appearance: Liquid

Concentration: 1 μg/μL

Description: mCherry IVT mRNA (m1Ψ substitution) is a highly optimized messenger RNA designed for efficient expression of the mCherry protein, a red fluorescent protein derived from Discosoma. This mRNA is produced through in vitro transcription (IVT) and features several key modifications to enhance its performance. The incorporation of N1-methyl-pseudouridine (m1Ψ) replaces natural uridine, which significantly reduces the immune response in mammalian cells while improving mRNA stability and translation efficiency. This modification has been shown to enhance protein expression levels, allowing for clearer detection of signals and better fold-change between ON and OFF states. The mRNA also features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which further enhance its stability and translation efficiency. These modifications collectively ensure that the mRNA remains stable and efficiently translated into the mCherry protein, which can be used for visualizing gene expression and cellular processes in real-time using fluorescence microscopy. As a reporter gene mRNA, mCherry IVT mRNA (m1Ψ substitution) is widely used in applications such as monitoring gene expression, studying cellular processes, and evaluating transfection efficiency in various cell types. It has been validated for high-level expression in cell culture, making it an ideal tool for both in vitro and in vivo studies.

CAT: BRP-02524

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase IVT mRNA is a high-performance, sequence-optimized messenger RNA designed for robust expression of firefly luciferase, a widely used bioluminescent reporter gene. This IVT mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The mRNA is produced through in vitro transcription (IVT) using a linearized plasmid template containing the firefly luciferase gene. The incorporation of these modifications ensures that the mRNA remains stable and efficiently translated into the luciferase protein, which can be used for visualizing gene expression and cellular processes in real-time using bioluminescence assays. As a reporter gene mRNA, HiExpress Firefly Luciferase IVT mRNA is widely used in applications such as monitoring gene expression, studying cellular processes, and evaluating transfection efficiency in various cell types. It has been validated for high-level expression in HEK293T cells, making it an ideal tool for both in vitro and in vivo studies. Its bioluminescent properties allow for sensitive detection of gene expression, making it a valuable tool for molecular biology and translational medicine.

CAT: BRP-02525

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase IVT mRNA (m1Ψ substitution) is a high-performance, sequence-optimized messenger RNA designed for robust expression of firefly luciferase, a widely used bioluminescent reporter gene. This IVT mRNA features the incorporation of N1-methylpseudouridine (m1Ψ), which replaces uridine to enhance mRNA stability, reduce immunogenicity, and improve translation efficiency. The mRNA also includes a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, further enhancing its stability and translation efficiency. This optimized mRNA has been validated for high expression levels in HEK293T cells, demonstrating significant luciferase activity at various time points post-transfection. Additionally, it has been shown to maintain effective expression in vivo, with detectable luciferase activity in C57BL/6 mice after intramuscular injection of LNP-encapsulated mRNA. The use of m1Ψ substitution has been found to increase protein expression levels and reduce the immune response, making it an ideal tool for both in vitro and in vivo studies. HiExpress Firefly Luciferase IVT mRNA (m1Ψ substitution) is suitable for applications such as monitoring gene expression, studying cellular processes, and evaluating mRNA delivery efficiency.

CAT: BRP-02526

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Gaussia Luciferase IVT mRNA is a high-performance, sequence-optimized messenger RNA designed for robust expression of Gaussia luciferase, a highly sensitive bioluminescent reporter gene. This IVT mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The mRNA is produced through in vitro transcription (IVT) using a linearized plasmid template containing the Gaussia luciferase gene. Gaussia luciferase is a monomeric enzyme containing only 185 amino acids, making it highly sensitive even at low expression levels. Unlike other luciferases (e.g., firefly luciferase) that are expressed intracellularly, Gaussia luciferase is a secreted reporter, meaning its activity can be measured without lysing the cells. This allows for real-time or time-course measurements and makes it suitable for downstream applications. Additionally, Gaussia luciferase is highly stable due to the presence of multiple disulfide bonds, making it suitable for applications under conditions of high temperature or the presence of specific chemicals. HiExpress Gaussia Luciferase IVT mRNA has been validated for high expression levels in HEK293T cells, demonstrating significant luciferase activity at various time points post-transfection. This optimized mRNA is suitable for applications such as monitoring gene expression, studying cellular processes, and evaluating mRNA delivery efficiency in both in vitro and in vivo settings.

CAT: BRP-02527

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Gaussia Luciferase IVT mRNA (m1Ψ substitution) is a high-performance, sequence-optimized messenger RNA designed for robust expression of Gaussia luciferase, a highly sensitive bioluminescent reporter gene. This IVT mRNA features the incorporation of N1-methylpseudouridine (m1Ψ) to replace uridine, which enhances mRNA stability, reduces immunogenicity, and improves translation efficiency. The mRNA also includes a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, further enhancing its stability and translation efficiency. Gaussia luciferase is a monomeric enzyme containing only 185 amino acids, making it highly sensitive even at low expression levels. Unlike other luciferases, Gaussia luciferase is secreted, allowing its activity to be measured without lysing the cells. This feature enables real-time or time-course measurements and makes it suitable for downstream applications. Additionally, Gaussia luciferase is highly stable due to the presence of multiple disulfide bonds, making it suitable for applications under conditions of high temperature or the presence of specific chemicals. HiExpress Gaussia Luciferase IVT mRNA (m1Ψ substitution) has been validated for high expression levels in HEK293T cells, demonstrating significant luciferase activity at various time points post-transfection. This optimized mRNA is suitable for applications such as monitoring gene expression, studying cellular processes, and evaluating mRNA delivery efficiency in both in vitro and in vivo settings.

CAT: BRP-02528

Appearance: Liquid

Concentration: 1 μg/μL

Description: hSpCas9 IVT mRNA is a high-performance messenger RNA designed for efficient expression of the humanized SpCas9 protein, a key component in CRISPR/Cas9 gene-editing systems. This IVT mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The mRNA is produced through in vitro transcription (IVT) using a linearized plasmid template containing the hSpCas9 gene. This optimized mRNA has been validated for high levels of Cas9 protein expression and efficient gene editing in various cell types, making it an ideal tool for both in vitro and in vivo gene-editing applications.

CAT: BRP-02529

Appearance: Liquid

Concentration: 1 μg/μL

Description: hSpCas9 IVT mRNA (m1Ψ substitution) is a highly optimized messenger RNA designed for robust expression of the humanized SpCas9 protein, a key component in CRISPR/Cas9 gene-editing systems. This IVT mRNA incorporates N1-methylpseudouridine (m1Ψ) to replace uridine, enhancing mRNA stability, reducing immunogenicity, and improving translation efficiency. It also features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, further enhancing stability and translation efficiency. This optimized mRNA has been validated for high levels of Cas9 protein expression and efficient gene editing in HEK293T cells, making it an ideal tool for both in vitro and in vivo gene-editing applications.

CAT: BRP-02530

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Chicken Ovalbumin IVT mRNA is a high-quality, codon-optimized and in vitro transcribed (IVT) messenger RNA designed for efficient expression of the chicken ovalbumin protein. This mRNA features a Cap 1 structure at the 5' end, validated 5' and 3' UTRs, and a 110 nt poly(A) tail, all of which enhance its stability and translation efficiency. These modifications ensure that the mRNA remains stable and efficiently translated into the ovalbumin protein, making it an ideal tool for various applications. Chicken ovalbumin is a well-characterized antigen commonly used in immunological studies, vaccine development, and gene therapy research. The HiExpress IVT mRNA is produced using a linearized plasmid template containing the ovalbumin gene, ensuring high fidelity and consistency in protein expression. This mRNA is suitable for both in vitro and in vivo experiments, providing a reliable platform for studying antigen expression and immune responses.

CAT: BRP-02531

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Ovalbumin IVT mRNA (m1Psi) is a high-performance, codon-optimized messenger RNA designed for efficient expression of the Ovalbumin protein, a commonly used antigen in immunological studies. This IVT mRNA incorporates N1-methylpseudouridine (m1Ψ) to replace uridine, which significantly enhances mRNA stability, reduces immunogenicity, and improves translation efficiency. This mRNA features a Cap 1 structure at the 5' end, validated 5' and 3' UTRs, and a 110 nt poly(A) tail, all of which enhance its stability and translation efficiency. These modifications collectively ensure robust protein expression and reduced immune activation, making it an ideal tool for applications in immunotherapy, vaccine development, and gene therapy. The incorporation of m1Ψ has been shown to effectively evade the innate immune response by blocking the recognition of RNA by pattern recognition receptors such as TLR3/7/8, RIG-I, and MDA-5. This feature is particularly important for therapeutic applications, as it allows for higher levels of protein expression without triggering adverse immune reactions. Additionally, m1Ψ has been demonstrated to increase the translation efficiency of mRNA, leading to higher protein yields.

CAT: BRP-02532

Appearance: Liquid

Concentration: 1 μg/μL

Description: Anti-hCD19-h28z CAR IVT mRNA is a specialized in vitro transcribed (IVT) messenger RNA designed to transiently express the anti-human CD19 chimeric antigen receptor (CAR) with the h28z signaling domain. This mRNA encodes a CAR protein that targets human CD19, a surface antigen commonly expressed on B cells, including those in various B-cell malignancies such as acute lymphoblastic leukemia (B-ALL). The CAR protein consists of a single-chain variable fragment (scFv) targeting human CD19, a CD8 transmembrane domain, and a co-stimulatory signaling domain composed of CD28 and CD3ζ fusion. This design allows for robust activation of T cells upon engagement with CD19-positive cells, leading to targeted killing of cancer cells. This IVT mRNA is optimized for efficient expression and stability. It is capped with Cap1, contains validated 5' and 3' untranslated regions (UTRs), and has a 110 nt poly(A) tail. These features enhance the mRNA's stability and translation efficiency, ensuring high levels of CAR protein expression. The validated 5' and 3' UTRs are crucial for optimizing translation initiation and mRNA stability, while the poly(A) tail further stabilizes the mRNA and promotes efficient translation. The transient expression of the CAR protein using IVT mRNA reduces the risk of long-term side effects associated with viral vector-based methods and provides a flexible platform for studying and developing CAR-T cell therapies. This approach is suitable for applications in cancer immunotherapy, where it can be used to transiently reprogram T cells to target and eliminate CD19-positive cancer cells.

CAT: BRP-02533

Appearance: Liquid

Concentration: 1 μg/μL

Description: Anti-hCD19-hBBz CAR IVT mRNA is a specialized in vitro transcribed (IVT) messenger RNA designed to transiently express the anti-human CD19 chimeric antigen receptor (CAR) with the hBBz signaling domain. This mRNA encodes a CAR protein that targets human CD19, a surface antigen commonly expressed on B cells, including those in various B-cell malignancies such as acute lymphoblastic leukemia (B-ALL). The CAR protein consists of a single-chain variable fragment (scFv) targeting human CD19, a CD8 transmembrane domain, and a co-stimulatory signaling domain composed of 4-1BB (CD137) and CD3ζ fusion. This design enhances T cell activation and persistence, leading to robust antitumor activity. This design has been shown to induce robust immune activation with lower levels of cytokine release and higher expression of anti-apoptotic proteins when compared to other CARs. The IVT mRNA is optimized for efficient expression and stability. It is capped with Cap1, contains validated 5' and 3' untranslated regions (UTRs), and has a 110 nt poly(A) tail. These features enhance the mRNA's stability and translation efficiency, ensuring high levels of CAR protein expression. The transient expression of the CAR protein using IVT mRNA reduces the risk of long-term side effects associated with viral vector-based methods and provides a flexible platform for studying and developing CAR-T cell therapies. This approach is suitable for applications in cancer immunotherapy, where it can be used to transiently reprogram T cells to target and eliminate CD19-positive cancer cells.

CAT: BRP-02534

Appearance: Liquid

Concentration: 1 μg/μL

Description: Anti-hCD19-hBBz CAR IVT mRNA (m1Psi) is a specialized in vitro transcribed (IVT) messenger RNA designed to transiently express the anti-human CD19 chimeric antigen receptor (CAR) with the hBBz signaling domain. This mRNA encodes a CAR protein that targets human CD19, a surface antigen commonly expressed on B cells, including those in various B-cell malignancies such as acute lymphoblastic leukemia (B-ALL). The CAR protein consists of a single-chain variable fragment (scFv) targeting human CD19, a CD8 transmembrane domain, and a co-stimulatory signaling domain composed of 4-1BB and CD3ζ fusion. This design has been shown to induce robust immune activation with lower levels of cytokine release and higher expression of anti-apoptotic proteins when compared to other CARs. The mRNA is capped with Cap1, contains validated 5' and 3' UTRs, and has a 110 nt poly(A) tail. These features enhance the mRNA's stability and translation efficiency, ensuring high levels of CAR protein expression. The incorporation of N1-methylpseudouridine (m1Ψ) further reduces immunogenicity and improves translation efficiency. This modification has been shown to effectively evade the innate immune response by blocking the recognition of RNA by pattern recognition receptors such as TLR3/7/8, RIG-I, and MDA-5. Additionally, m1Ψ has been demonstrated to increase the translation efficiency of mRNA, leading to higher protein yields. This IVT mRNA is suitable for applications in CAR-T cell therapy, where it can be used to transiently express the CAR protein in T cells. This transient expression approach reduces the risk of long-term side effects associated with viral vector-based methods and provides a flexible platform for studying and developing CAR-T cell therapies.

CAT: BRP-02535

Appearance: Liquid

Concentration: 1 μg/μL